FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug FilingZacks Investment Research • 09/22/25
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosisGlobeNewsWire • 09/22/25
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionGlobeNewsWire • 09/22/25
Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a studyGlobeNewsWire • 09/17/25
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track TagZacks Investment Research • 09/11/25
Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degenerationGlobeNewsWire • 09/11/25
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®PRNewsWire • 09/10/25
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetesGlobeNewsWire • 09/10/25
Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
SNY Down Despite Eczema Candidate Meeting Goal in Phase III StudyZacks Investment Research • 09/04/25
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'Investors Business Daily • 09/04/25
Sanofi shares sink over 9% on weak trial results for experimental inflammation drugReuters • 09/04/25
Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitisGlobeNewsWire • 09/04/25
Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopeniaGlobeNewsWire • 08/29/25
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related DiseaseZacks Investment Research • 08/15/25